Related Experiment Videos
Preventing renal bone disease in moderate renal failure with CaCO3 and 25(OH) vitamin D3
A Fournier1, A Idrissi, J L Sebert
1CHU Amines, Hôpital Lariboisiere, France.
Kidney International. Supplement
|March 1, 1988
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Neuropeptide Y potentiates the N-methyl-D-aspartate response in the CA3 dorsal hippocampus. II. Involvement of a subtype of sigma receptor.
The Journal of pharmacology and experimental therapeutics·1992
Nonadrenergic and noncholinergic arterial dilatation and venoconstriction are mediated by calcitonin gene-related peptide1 and neurokinin-1 receptors, respectively, in the mesenteric vasculature of the rat after perivascular nerve stimulation.
The Journal of pharmacology and experimental therapeutics·1992
Neuropeptide Y potentiates selectively the N-methyl-D-aspartate response in the rat CA3 dorsal hippocampus. I. Involvement of an atypical neuropeptide Y receptor.
The Journal of pharmacology and experimental therapeutics·1992
Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy.
Kidney international·1992
Effect of kidney disease on glucose handling (including genetic defects).
Kidney international. Supplement·2011
Need for better diabetes treatment for improved renal outcome.
Kidney international. Supplement·2011
Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.
Kidney international. Supplement·2011
SGLT2 inhibitors: molecular design and potential differences in effect.
Kidney international. Supplement·2011
Glucose handling by the kidney.
Kidney international. Supplement·2011
Bone: from a reservoir of minerals to a regulator of energy metabolism.
Kidney international. Supplement·2011